Sanofi Ventures Participates in $87 Million Series C Financing for VitriVax
Sanofi Ventures co-led an $87 million Series C financing round for VitriVax, Inc. to support the development of a Lyme disease vaccine candidate.
Stocks · News reference
Sanofi released its monthly disclosure regarding the total number of voting rights and shares as of October 31, 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Sanofi Ventures co-led an $87 million Series C financing round for VitriVax, Inc. to support the development of a Lyme disease vaccine candidate.
The global pharmaceutical market is valued at USD 1.88 trillion in 2026 and is projected to reach USD 3.20 trillion by 2035 at a CAGR of 6.10%. Growth is concentrated in obesity and oncology therapies, with U.S. pricing deals and Section 232 tariffs reshaping manufacturing. North America holds 42% of the market, while companies with strong positions in GLP-1 medicines and cancer therapies are growing significantly faster than the market.
The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.
Sanofi has signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance (pCPA) to expand public access to its multiple myeloma treatment, Sarclisa (isatuximab).
Sanofi is participating as a concurrent investor in the initial public offering of Windward Bio, a clinical-stage biotechnology company.